FGF21 and metabolic dysfunction-associated steatotic liver disease: Moreover, FGF-21 is garnering attention as a potential therapeutic target for obesity-related metabolic disorders, including NAFLD, owing to its significant effects on lipid and carbohydrate metabolism [88].